(0.16%) 5 222.68 points
(0.32%) 39 513 points
(-0.03%) 16 341 points
(-1.34%) $78.20
(-2.13%) $2.25
(1.14%) $2 366.90
(0.11%) $28.40
(1.48%) $1 005.50
(0.11%) $0.928
(-0.30%) $10.83
(-0.01%) $0.798
(-0.42%) $92.15
3 days till quarter result
(bmo 2024-05-14)
Expected move: +/- 11.55%
@ $7.03
Issued: 14 Feb 2024 @ 09:30
Return: -29.30%
Previous signal: Feb 13 - 09:30
Previous signal:
Return: 3.84 %
Live Chart Being Loaded With Signals
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines...
Stats | |
---|---|
Today's Volume | 139 452 |
Average Volume | 199 158 |
Market Cap | 132.84M |
EPS | $0 ( 2024-05-08 ) |
Next earnings date | ( $-0.890 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.860 |
ATR14 | $0.0150 (0.30%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Roth David | Sell | 10 451 | Common Stock |
2024-03-31 | Stephens Kristin | Buy | 11 666 | Common Stock |
2024-04-01 | Stephens Kristin | Sell | 4 218 | Common Stock |
2024-03-31 | Stephens Kristin | Sell | 11 666 | Restricted Stock Units |
2024-03-31 | Stephens Kristin | Buy | 2 000 | Common Stock |
INSIDER POWER |
---|
54.34 |
Last 100 transactions |
Buy: 2 824 203 | Sell: 497 307 |
Volume Correlation
Syros Pharmaceuticals Inc Correlation
10 Most Positive Correlations | |
---|---|
BOTJ | 0.855 |
NEPH | 0.851 |
BSBK | 0.846 |
CABA | 0.834 |
CCOI | 0.824 |
Z | 0.821 |
ZG | 0.817 |
FOLD | 0.814 |
HUBG | 0.812 |
PANL | 0.808 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Syros Pharmaceuticals Inc Correlation - Currency/Commodity
Syros Pharmaceuticals Inc Financials
Annual | 2023 |
Revenue: | $9.94M |
Gross Profit: | $7.68M (77.33 %) |
EPS: | $-5.81 |
FY | 2023 |
Revenue: | $9.94M |
Gross Profit: | $7.68M (77.33 %) |
EPS: | $-5.81 |
FY | 2022 |
Revenue: | $14.88M |
Gross Profit: | $11.91M (80.06 %) |
EPS: | $-3.90 |
FY | 2021 |
Revenue: | $23.49M |
Gross Profit: | $23.49M (100.00 %) |
EPS: | $-18.80 |
Financial Reports:
No articles found.
Syros Pharmaceuticals Inc
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators